Share Name Share Symbol Market Type Share ISIN Share Description
Indivior Plc LSE:INDV London Ordinary Share GB00BRS65X63 ORD USD0.10
  Price Change % Change Share Price Shares Traded Last Trade
  -0.10 -0.19% 51.84 1,780,562 16:35:01
Bid Price Offer Price High Price Low Price Open Price
51.70 51.98 53.40 50.28 50.90
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 788.08 218.00 29.80 1.8 378
Last Trade Time Trade Type Trade Size Trade Price Currency
17:14:48 O 19,026 51.843 GBX

Indivior (INDV) Latest News

More Indivior News
Indivior Takeover Rumours

Indivior (INDV) Share Charts

1 Year Indivior Chart

1 Year Indivior Chart

1 Month Indivior Chart

1 Month Indivior Chart

Intraday Indivior Chart

Intraday Indivior Chart

Indivior (INDV) Discussions and Chat

Indivior Forums and Chat

Date Time Title Posts
18/10/201919:11INDIVIOR THE PILL WITH NO CHEERS OR BEERS2,143
20/8/201916:28RB. de-merger 545
11/7/201908:29Johnson & Johnson court case oklahoma6
03/5/201910:16Judgement against insys2
31/7/201813:45Indivior (INDV) IP Battle Status -

Add a New Thread

Indivior (INDV) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-10-18 16:14:5151.8419,0269,863.65O
2019-10-18 15:48:5252.091,895987.18O
2019-10-18 15:48:2152.0969,05835,969.55O
View all Indivior trades in real-time

Indivior (INDV) Top Chat Posts

DateSubject
19/10/2019
09:20
Indivior Daily Update: Indivior Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker INDV. The last closing price for Indivior was 51.94p.
Indivior Plc has a 4 week average price of 44.19p and a 12 week average price of 43.50p.
The 1 year high share price is 223.50p while the 1 year low share price is currently 20.98p.
There are currently 728,306,837 shares in issue and the average daily traded volume is 2,579,783 shares. The market capitalisation of Indivior Plc is £377,554,264.30.
15/10/2019
09:41
florenceorbis: Share Price Information for Indivior (INDV) London Stock Exchange Share Price: 54.44 Bid: 54.44 Ask: 54.72 Change: 5.05 (10.22%)
30/9/2019
18:10
waldron: I set up this thread because i was interested in the potential of the company and products i still am, but for one reason or another i never got around to buying. Now for a bit of fun by using the past to perhaps predict the future by way of boxes, hopefully it will move upwards and onwards again like yesteryear 40 to 50p$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$$$ 50 to 60p 60 to 70p 70 to 80p 80 to 90p XMAS 2019 90 to 100p 100 to 110p XMAS 2020 LAST SEEN APPROX 8 APRIL 2019 110 to 120p 120 to 130p XMAS 2021 130 to 140p 140 to 150p 150 to 160p 160 to 170p 170 to 180p 180 to 190p 190 to 200p $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ 200 to 210p LAST SEEN APPROX 19 NOVEMBER 2018 300p LAST SEEN APPROX SEPTEMBER 2018 400p LAST SEEN APPROX JUNE 2018 500p LAST SEEN APPROX JUNE 2018 $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ 600p THE WORLD ACCORDING TO jimboau post1688 dated 19 Jul 2019 - 09:39 TO BE TARGETED FOR THE YEAR 2023,July sometime. $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ SHARE PRICE SUGGESTIONS MOST WELCOME togetherwith SENSIBLE TIME FRAMES WILL UPDATE AT END OF EACH MONTH $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ Https://www.marketscreener.com/INDIVIOR-19344116/ The intial push was on the 11th july 2019 from 44.30p with a high during the day of 62.76p eventually closing down again to 47.28p Friday 12th 2019 ended the day at 46.215p alittle down from the previous day which apparently gave some an opportunity to buy JULY/31/2019 | Interim 2019 Earnings Release Day ended the day snug in the 50 to 60p BOX at 54.80p AUGUST ENDS IN THE 60 to 70p BOX with 60.32p September 30th we be in the 40 to 50p BOX with 48.52p
06/9/2019
17:19
waldron: Share Price: 59.86 Bid: 60.22 Ask: 60.30 Change: -1.34 (-2.19%)
30/8/2019
17:30
waldron: I set up this thread because i was interested in the potential of the company and products i still am, but for one reason or another i never got around to buying. Now for a bit of fun by using the past to perhaps predict the future by way of boxes, hopefully it will move upwards and onwards again like yesteryear 50 to 60p 60 to 70p$$$$$$$$$$$ WE ARE HERE $$$$$$$$$$$$$$$$$ 70 to 80p 80 to 90p XMAS 2019 90 to 100p 100 to 110p XMAS 2020 LAST SEEN APPROX 8 APRIL 2019 110 to 120p 120 to 130p XMAS 2021 130 to 140p 140 to 150p 150 to 160p 160 to 170p 170 to 180p 180 to 190p 190 to 200p 200 to 210p LAST SEEN APPROX 19 NOVEMBER 2018 300p LAST SEEN APPROX SEPTEMBER 2018 400p LAST SEEN APPROX JUNE 2018 500p LAST SEEN APPROX JUNE 2018 600p THE WORLD ACCORDING TO jimboau post1688 dated 19 Jul 2019 - 09:39 TO BE TARGETED FOR THE YEAR 2023,July sometime. $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ SHARE PRICE SUGGESTIONS MOST WELCOME togetherwith SENSIBLE TIME FRAMES WILL UPDATE AT END OF EACH MONTH $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$ Https://www.marketscreener.com/INDIVIOR-19344116/ The intial push was on the 11th july 2019 from 44.30p with a high during the day of 62.76p eventually closing down again to 47.28p Friday 12th 2019 ended the day at 46.215p alittle down from the previous day which apparently gave some an opportunity to buy JULY/31/2019 | Interim 2019 Earnings Release Day ended the day snug in the 50 to 60p BOX at 54.80p AUGUST ENDS IN THE 60 to 70p BOX with 60.32p
31/7/2019
07:09
grupo: http://uk.advfn.com/stock-market/london/indivior-INDV/share-news/Indivior-PLC-Half-year-Report/80433734 FY 2019 Guidance -- On July 11, 2019 Indivior announced revised expectations for FY 2019 net revenue and net income following the stronger than expected H1 2019 net revenue performance. -- Consistent with the update, FY 2019 net revenue is expected to be in the range of $670m to $720m (previously: $525m to $575m) and net income in the range of $80m to $130m (previously: a loss of $40m to net income of $10m), excluding exceptional items and at constant exchange rates. -- Net revenue guidance assumes that share erosion of SUBOXONE(R) Film(2) and the authorized generic film product trend toward the rates of historical industry analogues over the remainder of FY 2019. -- All other key FY 2019 guidance elements are maintained, including: - SUBLOCADE(TM) net revenue of $50m to $70m; - Modest net revenue contribution from PERSERIS(TM); - Authorized generic buprenorphine/naloxone film contribution to net revenue in the tens of $-millions; - Operating expense (SG&A and R&D combined) of $440m to $460m (before exceptional costs), inclusive of costs relating to the current Legal Proceedings as described in Note 11 on pages 21-23; and, - A tax rate in the high-single to low double-digit range. Department of Justice Action -- On April 9, 2019, a federal grand jury in the Western District of Virginia indicted Indivior PLC and Indivior Inc. on charges of health care fraud, wire fraud, mail fraud, and conspiracy, in connection with the marketing and promotion practices, pediatric safety claims, and overprescribing of SUBOXONE(R) Film and/or SUBOXONE(R) Tablet by certain physicians. DOJ is seeking to recover $3 billion in monetary forfeitures and all assets derived from the commission of the alleged offenses. Indivior believes it has strong defences to the government's charges and will vigorously defend itself. On July 19, 2019, Indivior filed a Motion to Dismiss the indictment. It is not possible to predict with any certainty the potential impact of this litigation or to quantify the ultimate cost of a verdict or resolution, but it could have a material impact on the Group. -- Please see Notes 9, 10 and 11 beginning on page 20 for further details on Provisions, Contingent Liabilities and Legal Proceedings. Comment by Shaun Thaxter, CEO of Indivior PLC "2019 has been a uniquely complex and challenging year for Indivior, which has impacted all of our stakeholders. Set against this backdrop, I am pleased to report another quarter of strong execution and delivery against our strategic priorities. We have recently increased our FY 2019 guidance based on the outperformance of SUBOXONE(R) Film versus historical industry analogues(2) in the first half of the year, while at the same time continuing to make important strides in growing SUBLOCADE(TM) and PERSERIS(TM), the future value drivers of Indivior. We have also maintained our cost discipline resulting in a continued financial position that helps fortify against expected accelerated share loss of SUBOXONE(R) Film. Consistent with our stated priorities for SUBLOCADE(TM), further improvements were achieved in the overall prescription journey and in healthcare provider trial and adoption through our Addiction Sciences salesforce, which is now exclusively focused on SUBLOCADE(TM). Based on net revenues of $28m in the first half (including $17m in Q2), we are tracking comfortably towards our FY 2019 guidance of $50m-$70m. We are also pleased with continued positive anecdotal treatment provider feedback on PERSERIS(TM), our monthly risperidone injection for schizophrenia. Finally, I am incredibly proud of the way our employees have responded to Indivior's challenges. The strong business execution we are reporting today reflects our organization's resilience and dedication to delivering our Vision to improve the lives of patients suffering from addiction and its co-occurring disorders." 2. IMS Institute Report, January 2016; "Price Declines after Branded Medicines Lose Exclusivity in the U.S. Operating Review US Market Update The market for buprenorphine medication-assisted treatment (BMAT) products continued to grow at low double-digit rates in H1 2019 versus the comparable period in 2018. Market volume growth is benefiting both from increased overall public awareness of the opioid epidemic and approved treatments, and from regulatory and legislative changes that have expanded Opioid Use Disorder (OUD) treatment funding and treatment capacity. States are also realizing that providing treatment brings substantial value to both patients and society, but BMAT remains underutilized(3) . In response, both the number of physicians waivered to administer medication-assisted treatment and those able to treat to the permitted level of 275 patients (from 100 patients) continued to grow in H1 2019. The number of waivered nurse practitioners and physician assistants also continued to grow in H1 2019. Indivior supports efforts to encourage more eligible healthcare practitioners to provide treatment, and the Group continues to invest in expanding its compliance program to meet the growing number of BMAT prescribers and patients. On February 19, 2019, the market for generic buprenorphine/naloxone sublingual film products began to form rapidly after the Court of Appeals for the Federal Circuit (CAFC) vacated the preliminary injunction (PI) granted to Indivior against Dr. Reddy's Laboratories (DRL) and Alvogen Pine Brook LLC (Alvogen). There are now four generic buprenorphine/naloxone sublingual film products in the market: "at-risk" launches from DRL and Alvogen and additional generic film offerings, including Indivior's authorized generic buprenorphine/naloxone sublingual film product and one from Mylan N.V. The presence of these generics is not impacted by the recent ruling by Court of Appeals for the Federal Circuit (CAFC) on the '514, '150, and '832 patents. The CAFC upheld the decisions of the U.S. District Court for the District of Delaware finding that the asserted claims of the '514 Patent are valid but not infringed by DRL and Alvogen, and that the '150 Patent is valid but not infringed by DRL. The Court also upheld The District Court's decision that Actavis infringes the '514 patent. As a result of the launch of generic buprenorphine/naloxone sublingual film products, branded SUBOXONE(R) Film experienced significant market share loss in H1 2019, albeit at a lower rate than suggested by historical industry analogues(4) . SUBOXONE(R) Film market share exiting H1 2019 was 27% versus H1 2018 exit share of 52%. Overall commercial formulary access remains solid for SUBOXONE(R) Film. However, Indivior prudently assumes the pace of market share loss will intensify for branded SUBOXONE(R) Film, ultimately resulting in a branded market share position in-line with industry analogues(4) which suggests SUBOXONE(R) Film share loss could approach 90% in the coming 12 months. However, the timing for reaching this level is unknown at this point.
11/7/2019
17:15
waldron: Now for a bit of fun by using the past to perhaps predict the future by way of boxes 40 to 50p$$$$$$$$$$$ WE ARE STILL HERE$$$$$$$$$$$$$$$$$ 50 to 60p 60 to 70p$$$$$$$$$$$ WE WERE HERE$$$$$$$$$$$$$$$$$ 70 to 80p 80 to 90pXMAS 2019 90 to 100p 100 to 110p XMAS 2020 110 to 120p 120 to 130pXMAS 2021 First hurdle will be results at july end SHARE PRICE suggestions appreciated TOGETHER WITH SENSIBLE TIME FRAMES CERTAINLY WILL UPDATE IF TIMETABLE AHEAD OF SCHEDULE TO BE CONTINUED WITH POSSIBLE EXTRA COMMENT AND UPDATED ON A MONTHLY BASIS Https://www.marketscreener.com/INDIVIOR-19344116/ The intial push was on the 11th july 2019 from 44.30p with a high during the day of 62.76p eventually closing down again to 47.28p Http://uk.stoxline.com/q_uk.php?s=indv
11/7/2019
10:51
waldron: tariq_khan 11 Jul '19 - 10:46 - 1381 of 1382(premium) 0 1 0 Does this mean that INDV has to cough up money to pay some of the 1.4 billion fine, lionheart69uk1 11 Jul '19 - 10:48 - 1382 of 1382 0 1 0 Is there any chance that Indivior came to some negotiated settlement with Reckitt as otherwise why has the share price not shot up to over 100p? SENSIBLE QUESTIONS AND MIGHT WELL BE THE CASE AS TSMITH HAS MENTIONED tsmith2 11 Jul '19 - 10:36 - 1378 of 1378 0 2 0 When Indivior became a separate entity, the two companies agreed on a so-called mutual indemnity clause, under which Indivior would reimburse Reckitt for any liability imposed on the company for matters relating to its business, and vice versa.
04/7/2019
15:21
sarkasm: jonsols 4 Jul '19 - 07:34 - 1284 of 1285 0 0 0 Hmmm. Share price is based on future earnings. Regardless of whether INDV has or as not made provision in the books the share price includes a discount for the risk of adverse outcome. Single question for me is whether the market has under or over cooked the discount relative to the most likely outcome at this stage. Not an easy one to adjudge without intimate inside knowledge I would think... mwainw1973 4 Jul '19 - 14:37 - 1285 of 1285 0 0 0 So share price is not influenced by results? LOL In my opinion the share price is influenced by all things depending on the day Results,charts,news broker recommendation, trumptweets and the full moon not so much by whats posted here it being an illiquide share perhaps even the market makers hold sway
04/7/2019
07:34
jonsols: Hmmm. Share price is based on future earnings. Regardless of whether INDV has or as not made provision in the books the share price includes a discount for the risk of adverse outcome. Single question for me is whether the market has under or over cooked the discount relative to the most likely outcome at this stage. Not an easy one to adjudge without intimate inside knowledge I would think...
17/4/2019
21:22
floridamassive: One thing I don’t understand is after the standard life RNS came out, rather than going up, why the hell share price dropped by 4%?? Surely, it’s a good thing that they increased their stake in INDV!? Doesn’t make any sense? What am I missing here? share price has been behaving very strangely today.
Indivior share price data is direct from the London Stock Exchange
Your Recent History
LSE
INDV
Indivior
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191019 16:03:19